Therapy Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Ivonescimab |
| Synonyms | |
| Therapy Description |
Ivonescimab is a bispecific antibody that binds PD-1 and VEGFA, potentially resulting in antitumor activity (PMID: 37593227). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Ivonescimab | AK112|AK 112|AK-112|SMT112|SMT 112|SMT-112 | Immune Checkpoint Inhibitor 149 PD-L1/PD-1 antibody 124 VEGFA Antibody 5 | Ivonescimab is a bispecific antibody that binds PD-1 and VEGFA, potentially resulting in antitumor activity (PMID: 37593227). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05899608 | Phase III | Pembrolizumab Ivonescimab | Clinical Study of Ivonescimab for First-line Treatment of Metastatic Squamous NSCLC Patients | Recruiting | USA | POL | ITA | IRL | GRC | GBR | FRA | ESP | DEU | CAN | 2 |
| NCT06529718 | Phase II | Fluorouracil + Leucovorin + Oxaliplatin Ivonescimab | Testing Ivonescimab Versus FOLFOX in Advanced Biliary Tract Cancer Patients (SEVILLA) | Not yet recruiting | GBR | FRA | BEL | 0 |
| NCT06840834 | Phase II | Ivonescimab | Evaluating Ivonescimab As a Potential Treatment for Pleural Mesothelioma Patients Whose Cancer Has Returned After Previous Immunotherapy and Chemotherapy (Bi-MAPS) | Not yet recruiting | FRA | 0 |
| NCT06672575 | Phase Ib/II | Ivonescimab | A Phase I/II Study of IVONESCIMAB in Recurrent Glioblastoma | Recruiting | USA | 0 |
| NCT06805617 | Phase II | Ivonescimab | A Phase 2 Trial of Ivonescimab for Patients With Advanced, Metastatic Salivary Gland Cancers (I-MAC) | Not yet recruiting | USA | 0 |
| NCT04047290 | Phase I | Ivonescimab | A Study of AK112, a PD-1/VEGF Bispecific Antibody, for Advanced Solid Tumors | Completed | AUS | 0 |
| NCT06567314 | Phase II | Ivonescimab | Phase 2 Study of Ivonescimab in Patients With Cutaneous Squamous Cell Carcinoma | Recruiting | USA | 0 |
| NCT06767514 | Phase III | Pembrolizumab Ivonescimab | Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1 (HARMONi-7) | Recruiting | USA | 0 |
| NCT05382442 | Phase II | Ivonescimab Fluorouracil + Ivonescimab + Leucovorin + Oxaliplatin AK117 + Fluorouracil + Irinotecan + Ivonescimab + Leucovorin + Oxaliplatin AK117 + Fluorouracil + Ivonescimab + Leucovorin AK117 + Capecitabine + Ivonescimab + Oxaliplatin AK117 + Capecitabine + Ivonescimab Fluorouracil + Ivonescimab + Leucovorin AK117 + Ivonescimab Capecitabine + Ivonescimab + Oxaliplatin Fluorouracil + Irinotecan + Ivonescimab + Leucovorin + Oxaliplatin | A Study of AK112 With or Without AK117 in Metastatic Colorectal Cancer | Recruiting | USA | 1 |
CKB BOOST